08 jun: UBS Racks Up to $350 Million in Losses Related to Facebook IPO -S..
08 jun: Colombian Stocks Decline, Led By Ecopetrol; Peso Weakens
08-06-2012 23:47:00

J&J to Record $600 Million Charge Tied to Outstanding Lawsuits

Relateret indhold
Relateret debat
19 nov - 
Ingen tvivl om, at den forrentning er i orden for en AA..
19 nov - 
FK@ Den er noteret - men 7,48 % (år til dato) er en flo..
19 nov - 
Bare husk, at AAA-rating ikke altid er det mest passend..

By Ben Fox Rubin

Johnson & Johnson (JNJ) said it plans to record a special charge of roughly $600 million in its second quarter to increase its accrual for potential legal settlements, as it has faced a series of lawsuits over accusations of bribery and improper drug-marketing practices.

The company said the settlement payments stem for a series of outstanding civil cases that involve its drugs Risperdal, Invega and Natrecor, as well as nursing-home pharmacy operator Omnicare Inc. (OCR).

The health-care products company has faced lawsuits related to alleged off-label promotion of its antipsychotic treatment Risperdal, which was once J&J's top-selling drug before generic copycats hit the market, as well as legal challenges over off-label promotion of another schizophrenia treatment, Invega, and the heart-failure drug Natrecor.

Furthermore, the federal government is suing J&J, accusing it of paying kickbacks to induce Omnicare to encourage use of Risperdal and other J&J drugs.

In addition, J&J has dealt with state lawsuits regarding its promotion of Risperdal, including an Arkansas case in which the company in April was ordered to pay $1.2 billion after a jury found that J&J's past marketing of the drug violated the state's consumer-protection laws. J&J previously was ordered to pay $327 million in a South Carolina case and $258 million in Louisiana. The company is appealing all three cases.

In January, J&J agreed to settle a Texas case for $158 million.

Meanwhile, the company agreed to pay an $85 million fine in a criminal case regarding off-label marketing of Natrecor. Parallel civil litigation still hasn't been settled.

The company in April said its first-quarter earnings rose on a foreign-exchange-related gain tied to an acquisition and lower expenses.

Shares closed Friday at $62.98 and were unchanged after hours. The stock is down 4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 08, 2012 17:47 ET (21:47 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Intermail FY: Underskud nedbragt trods stort fald i omsætningen

18-12-2014 15:06:02
Intermail, der producerer konvolutter og forsendelseskoncepter, havde igen røde tal på bundlinjen i regnskabsåret 2013/14, hvor omsætningen styrtdykkede til 416..

Novo indgår forskningsaftale med amerikanere - NY

18-12-2014 14:19:37
Novo Nordisk har indgået en forskningsaftale med amerikanske Xencor om at udvikle nye biologiske medikamenter gennem Xencors teknologiplatform.Det fortæller det..

Aktier/åbning: Mærsk og Vestas øverst i kraftigt stigende C20

18-12-2014 09:23:01
Det danske aktiemarked suser torsdag ud af startblokken med kursstigninger til samtlige aktier i det ledende C20-indeks. Investeringslysten har sit udspring i U..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas har kurs mod canadisk milliardordre
2
Putin: Økonomiske problemer vil vare højst to år
3
Rublen hopper og danser før Putins årstale
4
Carlsberg/Berenberg: Sælg-anbefaling droppet - anbefaler hold
5
SAS Q4: Voldsomme særlige poster gav røde tal

Relaterede aktiekurser

Johnson & Johnson 106,20 2,1% Stigning i aktiekurs
Omnicare Inc 72,86 1,9% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.

Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. december 2014 21:59:16
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20141211.1 - EUROWEB2 - 2014-12-18 21:59:16 - 2014-12-18 21:59:16 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x